Akero Smashes Expectations in MASH, Showing Its Drug Reverses Fibrosis in Fatty Livers
Akero Therapeutics reported that at 96 weeks, 39% of patients who received the 50 mg dose of efruxifermin achieved improvement in fibrosis, or liver scarring, caused by the fatty liver disease MASH. This study previously failed to achieve statistically significant improvement at 36 weeks, but Akero executives say the latest results show that longer dosing matters. The post Akero Smashes Expectations in MASH, Showing Its Drug Reverses Fibrosis in Fatty Livers appeared first on MedCity News.
